Barclays analyst Balaji Prasad raised the firm’s price target on PolyPid to $10 from $2.50 and keeps an Equal Weight rating on the shares. The analyst says specialty pharma heads into Q3 earnings “in one of the weakest sentiments we have seen.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PYPD:
- PolyPid initiated with a Buy at H.C. Wainwright
- PolyPid regains compliance with Nasdaq minimum closing bid price rule
- PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
- PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023
- PolyPid announces publication of preclinical data on D-PLEX100
